Please login to the form below

Not currently logged in
Email:
Password:

Reckitt wins battle for Boots

Market analysts welcome Reckitt Benckiser's acquisition of BHI dubbing the deal as ìhard to faultî

Reckitt Benckiser has held off stiff competition from pharmaceutical multinationals to win the auction for Boots' over-the-counter medicines business with a higher than expected £1.93bn cash bid.

The deal, which will bring together Reckitt's Lemsip and Disprin cold remedies together with Boots' Nurofen painkiller, was concluded after the British group narrowly outbid Swiss company Novartis in the early hours of Friday (October 7). GlaxoSmithKline has confirmed that it was outbid in the last stage of the auction the previous day.

The final price was 22 times Boots Healthcare International's (BHI's) operating profits of £88m for the financial year to March 2005. Despite initial investor concerns that Reckitt had overpaid for BHI, analysts said the acquisition made sense.

ìStrategically the deal is hard to fault,î said Richard Workman at Oriel Securities. ìReckitt is buying good brands and has a good record on delivering on synergies.î

Reckitt chief executive, Bart Becht, said the company hopes to achieve cost-savings of £75m and £130m of net working capital gains by 2008, while the deal is expected to be earnings enhancing from the day it goes through (expected to be early next year), excluding a £150m one-off charge.

Boots was required to sell the healthcare business before it could merge with Alliance Unichem in a £7bn deal. Other pharmaceutical companies reported to have been interested in BHI were Pfizer and Bayer.

30th September 2008

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

Tree
Pharma’s vital role in sustainability and corporate social responsibility
Pharma is in the spotlight as tough questions about sustainability commitments continue to arise...
Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....